191 related articles for article (PubMed ID: 16253319)
21. Characterization of 3,4-methylenedioxypyrovalerone discrimination in female Sprague-Dawley rats.
Thomas AM; Cargile KJ; Lunn JA; Baker LE
Behav Pharmacol; 2021 Sep; 32(6):524-532. PubMed ID: 34397448
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats.
Gatch MB; Rutledge MA; Carbonaro T; Forster MJ
Psychopharmacology (Berl); 2009 Jul; 204(4):715-24. PubMed ID: 19288085
[TBL] [Abstract][Full Text] [Related]
23. Locomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents.
Gatch MB; Dolan SB; Forster MJ
Behav Pharmacol; 2016 Sep; 27(6):497-505. PubMed ID: 27028902
[TBL] [Abstract][Full Text] [Related]
24. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement.
Fletcher PJ; Korth KM; Robinson SR; Baker GB
Psychopharmacology (Berl); 2002 Jul; 162(3):282-91. PubMed ID: 12122486
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination.
Baker LE; Taylor MM
Pharmacol Biochem Behav; 1997 Aug; 57(4):737-48. PubMed ID: 9259001
[TBL] [Abstract][Full Text] [Related]
26. Effects of (+)-fenfluramine on 3,4-methylenedioxymethamphetamine (MDMA) discrimination in rats.
Baker LE; Makhay MM
Pharmacol Biochem Behav; 1996 Feb; 53(2):455-61. PubMed ID: 8808158
[TBL] [Abstract][Full Text] [Related]
27. MDMA-like stimulus effects of alpha-ethyltryptamine and the alpha-ethyl homolog of DOM.
Glennon RA
Pharmacol Biochem Behav; 1993 Oct; 46(2):459-62. PubMed ID: 7903460
[TBL] [Abstract][Full Text] [Related]
28. Interactions between 3,4-methylenedioxymethamphetamine and sigma1 receptors.
Brammer MK; Gilmore DL; Matsumoto RR
Eur J Pharmacol; 2006 Dec; 553(1-3):141-5. PubMed ID: 17070798
[TBL] [Abstract][Full Text] [Related]
29. Serotonin 5-HT1-like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine.
Callaway CW; Rempel N; Peng RY; Geyer MA
Neuropsychopharmacology; 1992 Sep; 7(2):113-27. PubMed ID: 1358088
[TBL] [Abstract][Full Text] [Related]
30. Differential substitution for the discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and methylphenidate in rats.
Mori T; Uzawa N; Kazawa H; Watanabe H; Mochizuki A; Shibasaki M; Yoshizawa K; Higashiyama K; Suzuki T
J Pharmacol Exp Ther; 2014 Aug; 350(2):403-11. PubMed ID: 24917544
[TBL] [Abstract][Full Text] [Related]
31. Stimulus effects of three sulfur-containing psychoactive agents.
Khorana N; Pullagurla MR; Dukat M; Young R; Glennon RA
Pharmacol Biochem Behav; 2004 Aug; 78(4):821-6. PubMed ID: 15301941
[TBL] [Abstract][Full Text] [Related]
32. Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.
Murnane KS; Murai N; Howell LL; Fantegrossi WE
J Pharmacol Exp Ther; 2009 Nov; 331(2):717-23. PubMed ID: 19684254
[TBL] [Abstract][Full Text] [Related]
33. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
Callahan PM; Appel JB
J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
[TBL] [Abstract][Full Text] [Related]
34. Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA.
Bubar MJ; Pack KM; Frankel PS; Cunningham KA
Psychopharmacology (Berl); 2004 May; 173(3-4):326-36. PubMed ID: 15064911
[TBL] [Abstract][Full Text] [Related]
35. Dopamine and serotonin antagonists fail to alter the discriminative stimulus properties of ±methylenedioxymethamphetamine.
Schenk S; Highgate Q
Behav Pharmacol; 2019 Jun; 30(4):327-334. PubMed ID: 30199389
[TBL] [Abstract][Full Text] [Related]
36. Disruption of the discriminative stimulus effects of S(+)-3,4-methylenedioxymethamphetamine (MDMA) by (+/-)-MDMA neurotoxicity: protection by fluoxetine.
Virden TB; Baker LE
Behav Pharmacol; 1999 Mar; 10(2):195-204. PubMed ID: 10780832
[TBL] [Abstract][Full Text] [Related]
37. Intravenous self-administration of mephedrone, methylone and MDMA in female rats.
Creehan KM; Vandewater SA; Taffe MA
Neuropharmacology; 2015 May; 92():90-7. PubMed ID: 25600245
[TBL] [Abstract][Full Text] [Related]
38. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement.
Fantegrossi WE; Ullrich T; Rice KC; Woods JH; Winger G
Psychopharmacology (Berl); 2002 Jun; 161(4):356-64. PubMed ID: 12073162
[TBL] [Abstract][Full Text] [Related]
39. Behavioral profiles in rats distinguish among "ecstasy," methamphetamine and 2,5-dimethoxy-4-iodoamphetamine: Mixed effects for "ecstasy" analogues.
Quinteros-Muñoz D; Sáez-Briones P; Díaz-Véliz G; Mora-Gutiérrez S; Rebolledo-Fuentes M; Cassels BK
Behav Neurosci; 2010 Oct; 124(5):662-76. PubMed ID: 20939666
[TBL] [Abstract][Full Text] [Related]
40. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats.
Kehne JH; Ketteler HJ; McCloskey TC; Sullivan CK; Dudley MW; Schmidt CJ
Neuropsychopharmacology; 1996 Aug; 15(2):116-24. PubMed ID: 8840347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
